期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 7, 期 1, 页码 21-25出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-011-0111-0
关键词
Chronic lymphocytic leukemia; CLL; Treatment; Older patients; Myelosuppression; Chemoimmunotherapy; GM-CSF; Rituximab; Fludarabine; Pentostatin; Lenalidomide; Chlorambucil; Alemtuzumab; Creatinine clearance; Tumor lysis; Infections; Hypogammaglobulinemia; Clinical trials; Antineoplastic agents
资金
- Celgene
- Hospira
- Genentech
- Gilead
Chronic lymphocytic leukemia (CLL) is typically a disease of older individuals. Yet most of the literature on various chemotherapeutic regimens includes patients who are 10 to 15 years younger than the median age at diagnosis of this disease. The older patient population is grossly underrepresented in clinical trials. Currently available therapies are often too toxic for this older patient population, so their efficacy is reduced. This review discusses some of the results of treatment in older patients with CLL. A discussion of factors that often affect outcome, such as comorbidities, renal function, bone marrow reserve, and infection, are also reviewed, along with quality of life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据